Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMS0ZBI)

Drug Name

AG-221 Drug Info

Synonyms

AG-221 (IDH2 inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 3	[1]
Acute myeloid leukaemia	2A60	Phase 1/2	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Isocitrate dehydrogenase (IDH)	TTDTWV0	IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Isocitrate dehydrogenase (IDH)	DTT	IDH1	9.383	7.391	8.851	7.299

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute myelogenous leukaemia

ICD Disease Classification

2A41

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Isocitrate dehydrogenase (IDH)	DTT	IDH1; IDH2; IDH3A; IDH3B; IDH3G	6.06E-02	0.11	0.24

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02273739) Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation. U.S.National Institutes of Health.
3	New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213.